12' MUCOSAL IMMUNITY

1
12. MUCOSAL IMMUNITY
2
(No Transcript)
3
(No Transcript)
4
(No Transcript)
5
(No Transcript)
6
(No Transcript)
7
(No Transcript)
8
(No Transcript)
9
13. TRANSPLANTATION
10
(No Transcript)
11
(No Transcript)
12
(No Transcript)
13
(No Transcript)
14
(No Transcript)
15
(No Transcript)
16
(No Transcript)
17
(No Transcript)
18
(No Transcript)
19
(No Transcript)
20
14. ANTI-TUMOUR IMMUNITY
21
(No Transcript)
22
(No Transcript)
23
(No Transcript)
24
(No Transcript)
25
(No Transcript)
26
(No Transcript)
27
15. REGULATION OF IMMUNE RESPONSES
28
(No Transcript)
29
(No Transcript)
30
(No Transcript)
31
(No Transcript)
32
(No Transcript)
33

34
MECHANISMS OF Treg
35
DEVELOPMENT AND SELECTION IN THYMUS ALSO
Treg!!!
36
(No Transcript)
37

38
(No Transcript)
39
(No Transcript)
40
(No Transcript)
41
(No Transcript)
42
BASIC DOGMA OF THE ADAPTIVE RESPONSE ANTIBODY
RESPONSES (B, Th2) EFFECTIVE AGAINST
EXTRACELLULAR PARASITESINFLAMMATORY RESPONSES
(Th1, Tc) EFFECTIVE AGAINST INTRACELLULAR
PARASITES MUTUAL COMPETITION Th1 vs. Th2
(REGULATION BY POSITIVE FEEDBACK)WRONG CHOICE
OF THE Th1 vs. Th2 RESPONSE
CAN BE FATAL (LEPROSY)
43
Th1 x Th2 (they dont like each other )IFNg
vs. IL-4
44

45
16. IMMUNOPATOLOGIC REACTIONS - ALLERGIES
46
(No Transcript)
47
(No Transcript)
48
(No Transcript)
49
(No Transcript)
50
(No Transcript)
51
(No Transcript)
52
Incidence of prototypical infectious diseases and
immune disorders 1950 to 2000
N Engl J Med, Vol 347, No. 12, 09/2002
53
HUGE INCREASE OF ALLERGIES AS
CIVILIZATION DISEASES Epidemiological studies
- hygienic hypothesis Early childhood on a
(primitive) farm (mycobacteria, LPS?) Intestinal
parasites Breast feeding Non/pasteurized milk
Good intestinal flora Hepatitis A Diesel
exhaust particles? Life style in general (DDR
vs. FRG, Turkish immigrants, anthroposophy..)
54
(No Transcript)
55
(No Transcript)
56
(No Transcript)
57
(No Transcript)
58
(No Transcript)
59
(No Transcript)
60
(No Transcript)
61
(No Transcript)
62
17. IMMUNOPATOLOGIC AUTOIMMUNE REACTIONS
63
(No Transcript)
64
(No Transcript)
65
(No Transcript)
66
(No Transcript)
67
(No Transcript)
68
(No Transcript)
69
18.IMMUNODEFICIENCIES
70
(No Transcript)
71
(No Transcript)
72
(No Transcript)
73
(No Transcript)
74
(No Transcript)
75
Nu/nu mouse (athymic)
76
(No Transcript)
77
(No Transcript)
78
(No Transcript)
79
(No Transcript)
80
(No Transcript)
81
(No Transcript)
82
(No Transcript)
83
(No Transcript)
84
(No Transcript)
85
19. IMMUNOPROPHYLAXIS AND IMMUNOTERAPY
86
(No Transcript)
87
(No Transcript)
88
(No Transcript)
89
(No Transcript)
90
(No Transcript)
91
(No Transcript)
92
(No Transcript)
93

94
MARKED SUCCESS THERAPEUTIC MONOCLONAL
ANTIBODIES Discovery 1976, Nobel prize
1984.Not patentedgt15 years technical
difficulties in therapeutic uses Last cca 10
years huge progress (humanized mAb), most
dynamic field of pharmaceutic industry, sales
over 20 billion USD per yearCca 30 approved
by FDA, other cca 100 under testing
95

96
(No Transcript)
97
(No Transcript)
98
HOPEFULLY IN FUTURE- BETTER VACCINES (HIV,
WEAK AND TUMOR ANTIGENS?)- BETTER
IMMUNOSUPPRESSION (AUTOIMMUNE DISEASES,
ALLERGIES, TRANSPLANTATION)- EFFECTIVE
IMMUNOTHERAPIES OF TUMOURS (A WEAK SPOT OF
IMMUNITY)
99
(No Transcript)
100
(No Transcript)
101
(No Transcript)
102
(No Transcript)
103
(No Transcript)